tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KPTI Stock Latest News

Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment
Company AnnouncementsKaryopharm Therapeutics Stockholders Approve Equity Plan Amendment
8d ago
8K
KPTI
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains
PremiumCompany Announcements
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains
22d ago
KPTI
Karyopharm abstract selected for presentation at 2025 EHA meeting
PremiumThe Fly
Karyopharm abstract selected for presentation at 2025 EHA meeting
23d ago
KPTI
Karyopharm price target lowered to $33 from $43 at RBC Capital
PremiumThe Fly
Karyopharm price target lowered to $33 from $43 at RBC Capital
24d ago
KPTI
Karyopharm price target lowered to $42 from $54 at Baird
PremiumThe Fly
Karyopharm price target lowered to $42 from $54 at Baird
24d ago
KPTI
Karyopharm price target adjusted to $10 from $5 at Barclays
PremiumThe FlyKaryopharm price target adjusted to $10 from $5 at Barclays
24d ago
KPTI
Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress
Premium
Company Announcements
Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress
25d ago
KPTI
Karyopharm reports Q1 EPS ($2.77), consensus ($3.09)
Premium
The Fly
Karyopharm reports Q1 EPS ($2.77), consensus ($3.09)
25d ago
KPTI
Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M
PremiumThe Fly
Karyopharm sees 2025 revenue $140M-$155M, consensus $149.62M
25d ago
KPTI
KPTI Earnings this Week: How Will it Perform?
PremiumPre-Earnings
KPTI Earnings this Week: How Will it Perform?
1M ago
KPTI
Biotech stocks slide as Marks resignation seen being negative for sector
PremiumThe Fly
Biotech stocks slide as Marks resignation seen being negative for sector
2M ago
DYN
MGX
Marks resignation ‘not good’ for biotech sector, says RBC
PremiumThe Fly
Marks resignation ‘not good’ for biotech sector, says RBC
2M ago
DYN
RNA
Karyopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler
PremiumThe FlyKaryopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler
3M ago
KPTI
Karyopharm price target lowered to $54 from $75 at Baird
Premium
The Fly
Karyopharm price target lowered to $54 from $75 at Baird
3M ago
KPTI
Karyopharm target adjusted to $7 from $56 at H.C. Wainwright
Premium
The Fly
Karyopharm target adjusted to $7 from $56 at H.C. Wainwright
3M ago
KPTI
Karyopharm trading halted, news pending
PremiumThe Fly
Karyopharm trading halted, news pending
3M ago
KPTI
Karyopharm implementing 1-for-15 reverse stock split
PremiumThe Fly
Karyopharm implementing 1-for-15 reverse stock split
3M ago
KPTI
Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures
PremiumRatings
Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures
3M ago
KPTI
Karyopharm’s Earnings Call: Growth Amid Financial Challenges
PremiumCompany Announcements
Karyopharm’s Earnings Call: Growth Amid Financial Challenges
4M ago
KPTI
Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating
PremiumRatingsKaryopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating
4M ago
KPTI
Karyopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for Funding
Premium
Company Announcements
Karyopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for Funding
4M ago
KPTI
Karyopharm’s 2024 Earnings and Clinical Progress
Premium
Company Announcements
Karyopharm’s 2024 Earnings and Clinical Progress
4M ago
KPTI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >